Chicago Capital LLC boosted its holdings in Edwards Lifesciences Corp (NYSE:EW) by 12.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 210,890 shares of the medical research company’s stock after purchasing an additional 24,131 shares during the quarter. Edwards Lifesciences makes up about 2.5% of Chicago Capital LLC’s investment portfolio, making the stock its 6th largest holding. Chicago Capital LLC owned about 0.10% of Edwards Lifesciences worth $36,716,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Bank Hapoalim BM boosted its holdings in shares of Edwards Lifesciences by 10.4% during the second quarter. Bank Hapoalim BM now owns 3,730 shares of the medical research company’s stock valued at $543,000 after acquiring an additional 350 shares during the period. Janney Montgomery Scott LLC boosted its holdings in shares of Edwards Lifesciences by 2.2% during the second quarter. Janney Montgomery Scott LLC now owns 16,336 shares of the medical research company’s stock valued at $2,378,000 after acquiring an additional 355 shares during the period. Wendell David Associates Inc. boosted its holdings in shares of Edwards Lifesciences by 4.0% during the second quarter. Wendell David Associates Inc. now owns 9,548 shares of the medical research company’s stock valued at $1,390,000 after acquiring an additional 363 shares during the period. Park Avenue Securities LLC boosted its holdings in shares of Edwards Lifesciences by 9.6% during the second quarter. Park Avenue Securities LLC now owns 4,411 shares of the medical research company’s stock valued at $645,000 after acquiring an additional 387 shares during the period. Finally, Tyers Asset Management LLC boosted its holdings in shares of Edwards Lifesciences by 6.1% during the second quarter. Tyers Asset Management LLC now owns 6,832 shares of the medical research company’s stock valued at $995,000 after acquiring an additional 392 shares during the period. 82.71% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE EW opened at $149.75 on Tuesday. Edwards Lifesciences Corp has a fifty-two week low of $102.00 and a fifty-two week high of $175.00. The company has a current ratio of 2.31, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18. The stock has a market cap of $31.94 billion, a P/E ratio of 39.41, a P/E/G ratio of 2.01 and a beta of 0.87.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.05. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The business had revenue of $906.60 million for the quarter, compared to analysts’ expectations of $927.56 million. During the same period in the previous year, the business earned $0.84 earnings per share. The company’s revenue was up 10.4% on a year-over-year basis. As a group, analysts predict that Edwards Lifesciences Corp will post 4.69 earnings per share for the current fiscal year.
In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $144.02, for a total value of $4,738,258.00. Following the sale, the chief executive officer now directly owns 76,026 shares in the company, valued at $10,949,264.52. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 700 shares of the business’s stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $142.64, for a total transaction of $99,848.00. Following the completion of the sale, the vice president now owns 27,772 shares in the company, valued at $3,961,398.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 116,511 shares of company stock worth $16,634,402. Company insiders own 1.84% of the company’s stock.
EW has been the subject of several analyst reports. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Saturday, July 14th. Guggenheim reissued a “buy” rating and set a $170.00 price target on shares of Edwards Lifesciences in a report on Friday, July 27th. Jefferies Financial Group reissued a “buy” rating and set a $168.00 price target on shares of Edwards Lifesciences in a report on Friday, July 27th. ValuEngine raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Wednesday, September 19th. Finally, SunTrust Banks reduced their price target on shares of Edwards Lifesciences to $170.00 and set a “buy” rating for the company in a report on Friday, August 10th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $156.79.
TRADEMARK VIOLATION NOTICE: “Edwards Lifesciences Corp (EW) is Chicago Capital LLC’s 6th Largest Position” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/11/06/edwards-lifesciences-corp-ew-is-chicago-capital-llcs-6th-largest-position.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
See Also: How to Use a Moving Average for Trading
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.